This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

JUL 1 9 2002

Patent Attorney's Docket No. 033072-022

N THE UST TED STATES PATENT AND TRADEMARK OFFICE

034

In	re	Patent	Application	of

Larry S. BARAK et al.

Group Art Unit: 1645

RECEIVED

Application No.: 10/054,616

Examiner: Unassigned

JUL 2 3 2002

Filed: January 22, 2002

Confirmation No.: 7096

TECH CENTER 1600/2900

For: Constitutively Desensitized G Protein-Coupled Receptors

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement, Supplemental Information Disclosure Statement and accompanying forms PTO-1449 for the above-identified patent application.

[X] No additional fee for submission of an IDS is required.

[] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

[] A certification under 37 C.F.R. § 1.97(e) is also enclosed.

[] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1:17(p) are also enclosed.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (919) 941-9240

Date: July 18 2002

Melissa M. Hayworth

Registration No. 45,774



TITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Larry S. BARAK et al. Group Art Unit: 1645 Application No.: 10/054,616 Examiner: Unassigned Filed: January 22, 2002 Confirmation No.: 7096 For: Constitutively Desensitized G Protein-Coupled Receptors

TO THE STATE OF TH

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, the documents submitted herewith were cited in the application and are being provided for the Examiner's convenience.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, VA 22313-1404

Phone: (919) 941-9240

Date: July 18, 2002

Registration No. 45,774

2 . A!

Substitute for form 1449A/PTO INFORMATION DISCLOS
STATEMENT BY ARRUN ATTORNEY'S DKT NO APPLICATION NO. 033072-022 10/054,616 APPLICANT Larry S. Barak, et al. FILING DATE GROUP January 22, 2002 1645

		• .	U.S. PATENT DOCUMENTS				
	U.S. Patent D	ocument					_
Examiner Initials	Kind Code Number (if known)		Name of Patentee or Applicant of Cited Document		Date of Publication (MM-DD-YYYY)		
	6,150,393		Behan, et al.		11-21-2000		
	6,140,509		Behan, et al.	ehan, et al.		00-31-2000	
	6,110,693		Barak, et al.		08-29-2000		
	6,107,324		Behan, et al.		08-22-2000		
-	6,066,476		Tsien, et al.		05-23-2000		
	5,891,646		Barak, et al.		04-06-1999		
	5,777,079		Tsien, et al.		07-07-1998		
_	5,767,337		Roses, et al.		06-16-1998		
	5,719,262		Buchardt, et al.		02-17-19	98	
	5,714,331	5,714,331 Buchardt, et al.		02-03-1998			
	5′,665,710		Rahman, et al.		09-09-1997		
	5,625,048		Tsien, et al.		04-29-1997		
	5,602,240 De Mesmaeker, et al.		02-11-1997				
		FC	REIGN PATENT DOCUMENTS	3			
	Foreign Patent			1			
Examiner Initials	Number	Kind Code (if known)	Country		ate of Publication MM-DD-YYYY)	Trans Yes	atio
	WO 00/12704	A2	РСТ	03-09-	2000		
	WO 96/40062	A1	PCT 12-19-1		1996		
·	WO 94/26764	A1	PCT 11-24-		1994	√abstract	
	WO 93/24510	A1	PCT	12-09-	1993	√abstract	
		NO	N PATENT LITERATURE DOCUMENT	s			
Examiner Initials	include i item (book,	name of author magazine, jouri	(in CAPITAL LETTERS), title of the a nal, serial, symposium, catalog, etc.), publisher, city and/or country where	date, page	e(s), volume-issue numl	he ber(s),	
	ANGERS, S., et al., Detection of β_2 -Adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET), Proceedings of the National Academy of Sciences, Vol 97, No. 7, March 28, 2000, pp. 3684-3689, Proc.Natl. Acad. Sci, USA.						
	ATTRAMADAL, H., et al., β-Arrestin2, a Novel Member of the Arrestin/β-Arrestin Gene Family, Journal of Biological Chemistry, Vol 257, No. 25, September 5, 1992, pp 17882-17890, The American Society for Biochemistry and Molecular Biology, Inc., USA.						
	BARAK, L.S., et al., A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation, Journal of Biological Chemistry, Vol. 272, No. 44, October 31, 1997, pp. 27497-27500, The American Society for Biochemistry and Molecular Biology, Inc., USA.						
	BARAK, L.S., et al., Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus, Proceedings of the National Academy of Sciences, Vol 98, No. 1, January 2, 2001, pp. 93-98, Proc.Natl. Acad. Sci, USA.						
	BARAK, L.S., et al., Fluorescent Protein (Internal Traffici Conjugate, <u>Mol</u> e	king and Surface Mobility of a Function Secular Pharmacology, 51, 1997, pp. 1	nally Intac 77-184.	t β ₂ -Adrenergic Recept	or-Green	,
xaminer ignature			Date Considered	Ī			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO. 033072-022

APPLICATION No. 10/054,616

APPLICANT

Larry S. Barak, t al. FILING DATE January 22, 2002

GROUP

2FCENED

JUL 1 9 2002

"" 5 3 5005

F		9/	LLC DATENT DOO	INACAITA	JIL 2 3 2002	
F	THE PARTY OF THE P	<u> </u>	U.S. PATENT DOC	JMENTS	1600/C	
Examiner Initials		Kind Code (if known)	Name of Patento		TECH CENTER 1600/2 TECH CENTER 1600/2 (MM-DD-YYYY) 10-29-1996	
	5,569,827		Kessous-Elbaz, et a		10-29-1996	
	5,569,824		Donehower, et al.		10-29-1996	
	5,539,082		Nielsen, et al.		07-23-1996	
	5,264,221		Tagawa, et al.		11-23-1993	
	5,034,506		Summerton, et al.		07-23-1991	
	4,816,567		Cabilly, et al.		03-28-1989	
	4,816,397		Boss, et al.		03-28-1989	
	4,493,795		Nestor, Jr., et al.		01-15-1985	
_	4,342,566		Theofilopoulos, et a	ıl.	08-03-1982	
		NON F	ATENT LITERATURE			
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. BARAK, L.S., et al., Real-time Visualization of the Cellular Redistribution of G Protein-coupled Receptor Kinase 2 and					
	arrestin 2 during Homologous Desensitization of the Substance P Receptor, <u>Journal of Biological Chemistry</u> , Vol. 274, No. 11, March 12, 1999, pp. 7565-7569, The American Society for Biochemistry and Molecular Biology, Inc., USA.					
	Current Protocols in Molecular Biology, Vol. 1, Section II, Supplement 24, 6.3.1-6.3.6, 1993, John Wiley & Sons, N					
	DREWS, J., <i>Drug Discovery: A Historical Perspective</i> , Science, Vol. 287, March 17, 2000, pp. 1960-1964, Americal Association for the Advancement of Science, Washington, D.C.					
	FERGUSON, S.S.G., et al., <i>G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins</i> , Can. J. Physiol. Pharmacol., Vol. 74, 1996, pp. 1095-1110, NRC, Canada.					
	arrestins, Can. J. Ph	ysiol. Pharmace	<u>ol., Vol. 74, 1996, pp. 10</u>	<i>tion: role of G</i> 195-1110, NR	-protein-coupled receptor kinases and C, Canada.	
	FERGUSON, S.S.G.,	ysiol. Pharmac et al., <i>Role of</i> try, Vol 270, N	<u>ol., Vol. 74, 1996, pp. 10</u> Phosphorylation in Agonis	tion: role of G 195-1110, NR t-promoted β-	e-protein-coupled receptor kinases and C, Canada.	
	FERGUSON, S.S.G., of Biological Chemis and Molecular Biolog HARADA, A., et al.,	ysiol. Pharmace et al., Role of try, Vol 270, N yy, Inc., USA. Altered microte	ol., Vol. 74, 1996, pp. 10 Phosphorylation in Agonis o. 42, October 20, 1995,	tion: role of G 195-1110, NR t-promoted β_2 pp. 24782-2	e-protein-coupled receptor kinases and C, Canada. Adrenergic Receptor Sequestration, Journ 4789, The American Society for Biochem	
	arrestins, Can. J. Ph FERGUSON, S.S.G., of Biological Chemis and Molecular Biolog HARADA, A., et al., 369, No. 6480, Jun KIM, KM., et al., D and β-arrestins, Jour	ysiol. Pharmaci et al., Role of try, Vol 270, N y, Inc., USA. Altered microti e 9, 1994, Mac ifferential Regunal of Biologica	pol., Vol. 74, 1996, pp. 10 Phosphorylation in Agonis to. 42, October 20, 1995, who be a subjected in small cmillian Magazines, Ltd., I dation of the Dopamine D.	tion: role of G 195-1110, NR it-promoted β_2 pp. 24782-2 ll-calibre axons ondon.	g-protein-coupled receptor kinases and C, Canada. Adrenergic Receptor Sequestration, Journ 4789, The American Society for Biochemics of mice lacking tau protein, Nature, Vol.	
	arrestins, Can. J. Ph FERGUSON, S.S.G., of Biological Chemis and Molecular Biolog HARADA, A., et al., 369, No. 6480, Jun. KIM, KM., et al., D and β-arrestins, Jour Society for Biochemi LAPORTE, S.A., et al.	et al., Role of try, Vol 270, Ny, Inc., USA. Altered microtice 9, 1994, Macifferential Regunal of Biological stry and Molecular, The β ₂ -Adreidings of the Na	pol., Vol. 74, 1996, pp. 10 Phosphorylation in Agonis to. 42, October 20, 1995, ubule organization in smale emillian Magazines, Ltd., I dation of the Dopamine D. I Chemistry, Vol 276 No. ular Biology, Inc., USA.	tion: role of G 95-1110, NR tt-promoted β_2 pp. 24782-2 Il-calibre axon. ondon. and D_3 Rece, 40, October	g-protein-coupled receptor kinases and C, Canada. Adrenergic Receptor Sequestration, Journ 4789, The American Society for Biochemics of mice lacking tau protein, Nature, Vol.	
	arrestins, Can. J. Ph FERGUSON, S.S.G., of Biological Chemis and Molecular Biolog HARADA, A., et al., 369, No. 6480, Jun. KIM, KM., et al., D and β-arrestins, Jour Society for Biochemi LAPORTE, S.A., et a endocytosis, Proceed Proc.Natl. Acad. Sci, LAPORTE, S. A., et a Adrenergic Receptor	et al., Role of try, Vol 270, Ny, Inc., USA. Altered microtice 9, 1994, Macifferential Regunal of Biological stry and Molecular, The β_2 -Adrendings of the Na, USA. al., The Interactinto Clathrin-cointo Clathrin-cointy	ol., Vol. 74, 1996, pp. 10 Phosphorylation in Agonis to. 42, October 20, 1995, Tubule organization in smale millian Magazines, Ltd., I Tation of the Dopamine D, The Chemistry, Vol 276 No. Tular Biology, Inc., USA. The Company of Science The Company of Beaution of β-Arrestin with the Total Pits, Journal of Biology	tion: role of G 195-1110, NR tt-promoted β_2 pp. 24782-2 tl-calibre axon. condon. and D_3 Receptor 40, October 1 complex recrues, Vol 96, No.	reprotein-coupled receptor kinases and C, Canada. Adrenergic Receptor Sequestration, Journal 4789, The American Society for Biochemics of mice lacking tau protein, Nature, Vol. 1990, pp. 37409-97414, The American 1991, pp. 37409-97414, The American 1991, pp. 3712-3717, pp. 7. March 30, 1999, pp. 3712-3717, pp. 18 Required for the Clustering of β ₂ -try, Vol. 275, No. 30, July 28, 2000, pp.	
	arrestins, Can. J. Ph FERGUSON, S.S.G., of Biological Chemis and Molecular Biolog HARADA, A., et al., 369, No. 6480, Jun KIM, KM., et al., D and β-arrestins, Jour Society for Biochemi LAPORTE, S.A., et a endocytosis, Proceece Proc.Natl. Acad. Sci, LAPORTE, S. A., et a Adrenergic Receptor 23120-23126, The	et al., Role of try, Vol 270, Ny, Inc., USA. Altered microtice 9, 1994, Macifferential Regunal of Biological stry and Molecular, The β ₂ -Adrendings of the Na, USA. al., The Interactinto Clathrin-color American Socie Arrestin: A Pro	ol., Vol. 74, 1996, pp. 10 Phosphorylation in Agonis to. 42, October 20, 1995, Tubule organization in smale millian Magazines, Ltd., I Plation of the Dopamine D. The Chemistry, Vol 276 No. The Siology, Inc., USA. The Siology, Inc., USA. The Siology of Science The Siology of Science The Siology of Science The Siology of Siology	tion: role of G 95-1110, NR 1t-promoted β_2 pp. 24782-2 Il-calibre axon. ondon. and D_3 Receptor (40, October 15) complex recrues, Vol 96, Notate 16, AP-2 Adapto ogical Chemis Molecular Biole	a-protein-coupled receptor kinases and C, Canada. -Adrenergic Receptor Sequestration, Journ 4789, The American Society for Biochemics of mice lacking tau protein, Nature, Vol. 1990, pp. 37409-97414, The American 1991, pp. 37409-97414, The American 1991, pp. 3712-3717, pp. 37409-97414, The Clustering of β ₂ -try, Vol. 275, No. 30, July 28, 2000, pp. 1991, pp. 3712-3717, pp. 375, No. 30, July 28, 2000, pp. 1992, pp. 3712-3717, pp. 375, No. 30, July 28, 2000, pp. 3712-3717, pp. 375, No. 30, July 28, 2000,	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

Signature

INFORMATION DISCLOSURE STATEMENT & APPLICANT

ATTORNEY'S DKT NO.	APPLICATION No.		
033072-022	10/054,616		
APPLICANT			
Larry S. Barak, et al.			
FILING DATE	GROUP		
January 22, 2002	1645		

	グ、					
Examiner Initials	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	MÉNARD, L., et al., Synergistic Regulation of $β_2$ -Adrenergic Receptor Sequestration: Intracellular Complement of $β_2$ -Adrenergic Receptor Kinase and β-Arrestin Determine Kinetics of Internalization, Molecular Pharmacology, Vol. 51, No. 5, May 1997, pp. 800-808, The American Society for Pharmacology and Experimental Therapeutics.					
	MHAOUTY-KODJA, S., et al., Constitutively Active Alpha-1b Adrenergic Receptor Mutants Display Different Phosphorylation and Internalization Features, Molecular Pharmacology, Vol. 55, No. 2, February 1999, pp. 339-347, The American Society for Pharmacology and Experimental Therapeutics.					
!	OAKLEY, R.H., et al., Association of β-Arrestin with G Protein-coupled Receptors during Clathrin-mediated Endocytosis Dictates the Profile of Receptor Resensitization, Journal of Biological Chemistry, Vol 274, No. 45, November 5, 1999, pp. 32248-32257, The American Society for Biochemistry and Molecular Biology, Inc., USA.					
!	OAKLEY, R.H., et al., Differential Affinities of Visual Arrestin, β-Arrestin1, and β-Arrestin2 for G Protein-coupled Receptors Delineate Two Major Classes of Receptors, Journal of Biological Chemistry, Vol 275, No. 22, June 2, 2000, pp. 17201-17210, The American Society for Biochemistry and Molecular Biology, Inc., USA.					
	OAKLEY, R.H., et al., Molecular Determinatnts Underlying the Formation of Stable Intracellular G Protein-coupled Receptor - β-Arrestin Complexes after Receptor Endocytosis, Journal of Biological Chemistry, Vol 276, No. 22, June 1, 2001, pp. 19452 - 19460, The American Society for Biochemistry and Molecular Biology, Inc., USA.					
	PROBST, W.C., et al., Sequence Alignment of the G-Protein Coupled Receptor of Superfamily, DNA and Cell Biology, Vol. 11, No. 1, January & February 1992, pp. 1-20, Mary Ann Liebert, Inc. Publishers.					
	SADEGHI, H.M., et al., <i>Maturation of Receptor Proteins in Eukaryotic Expression Systems</i> , <u>Journal of Receptor & Signal Transduction Research</u> , Vol. 17, No 1-3, 1997, pp. 433-445, Marcel Dekker, Inc., USA.					
	SADEGHI, H., et al., <i>O-Glycosylation of the V2 vasopressin receptor</i> , Glycobiology, Vol 9, No. 7, pp. 731-737, 1999, Oxford University Press, Printed by the Sheridan Press, USA.					
	SCHÖNEBERG, T., et al., Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide, Embo Journal, Vol 15, No. 6, pp. 1283-1291, 1996, Oxford University Press.					
	SCHÖNEBERG, T., et al., V2 Vasopressin Receptor Dysfunction in Nephrogenic Diabetes Insipidus Caused by Different Molecular Mechanisms, Human Mutation, Vol 12, No. 3, pp. 196-205, 1998, Willey-Liss, Inc.					
	CHI W I Chadrate And I would be a second and a second					
	SHI, W., et al., Rhodopsin Arginine-135 Mutants Are Phosphorylated by Rhodopsin Kinase and Bind Arrestin in the Absence of 11-cis-Retinal, Biochemistry, Vol 37, pp. 4869-4874, 1998, American Chemical Society, Washington, D.C.					
	ZHANG, J., et al., Cellular Trafficking of G Protein-coupled Receptor/ β-Arrestin Endocytic Complexes, <u>Journal of Biological Chemistry</u> , Vol 274, No. 16, April 16, 1999, pp. 10999-11006, The American Society for Biochemistry and Molecular Biology, Inc., USA.					
	ZHANG, J., et al., A Central Role for β -Arrestins and Clathrin-coated Vesicle-mediated Endocytosis in β_2 -Adrenergic Receptor Resensitization, Journal of Biological Chemistry, Vol. 272, No. 43, October 24, 1997, pp. 27005-27014, The American Society for Biochemistry and Molecular Biology, Inc., USA.					
Examiner	Date					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Considered

RECEIVED

JUL 2 3 2002

TECH CENTER 1600/2900